Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

347
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
347
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

1.2K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
1.2K
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

368
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
368
Other Pulmonary Disorders01:17

Other Pulmonary Disorders

923
Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.
923
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

3.2K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
3.2K
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

666
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
666

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acute exacerbation in fibrotic interstitial lung disease: An International Working Group Report.

American journal of respiratory and critical care medicine·2026
Same author

Real-world persistence with antifibrotic treatments: a nationwide study on claims data in France (The REPEAT study).

Respiratory research·2026
Same author

Lung disease in rheumatoid arthritis.

Nature reviews. Rheumatology·2026
Same author

Progressive pulmonary fibrosis: a state-of-the-art review.

The European respiratory journal·2026
Same author

Mixed/combined pulmonary non-small cell carcinoma and carcinoid: State-of-the-Art review of clinical, histological, and molecular features with therapeutic implications.

Histology and histopathology·2026
Same author

Expert Perspectives: Defining and Managing Progressive Pulmonary Fibrosis in Systemic Sclerosis.

Arthritis & rheumatology (Hoboken, N.J.)·2026

Related Experiment Video

Updated: Sep 29, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.3K

Drug-induced interstitial lung disease.

Paolo Spagnolo1, Philippe Bonniaud2,3, Giulio Rossi4

  • 1Respiratory Disease Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, member of ERN Lung, Padova, Italy paolo.spagnolo@unipd.it.

The European Respiratory Journal
|March 25, 2022
PubMed
Summary

Drug-induced interstitial lung disease (DI-ILD) is a growing concern, linked to various medications including biologics. Early detection and drug cessation are key, with steroids used for severe cases.

More Related Videos

Direct Intrabronchial Administration to Improve the Selective Agent Deposition Within the Mouse Lung
07:10

Direct Intrabronchial Administration to Improve the Selective Agent Deposition Within the Mouse Lung

Published on: May 20, 2019

13.9K
Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
11:36

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Published on: May 29, 2020

3.1K

Related Experiment Videos

Last Updated: Sep 29, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.3K
Direct Intrabronchial Administration to Improve the Selective Agent Deposition Within the Mouse Lung
07:10

Direct Intrabronchial Administration to Improve the Selective Agent Deposition Within the Mouse Lung

Published on: May 20, 2019

13.9K
Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
11:36

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Published on: May 29, 2020

3.1K

Area of Science:

  • Pulmonology
  • Pharmacology
  • Toxicology

Background:

  • Drug-induced interstitial lung disease (DI-ILD) is an escalating cause of illness and death.
  • Numerous medications, including novel biologics, chemotherapeutics, and immune checkpoint inhibitors, are implicated in DI-ILD.
  • DI-ILD presents diverse clinical patterns, from mild symptoms to fatal respiratory failure.

Purpose of the Study:

  • To review the current understanding of drug-induced interstitial lung disease.
  • To highlight the diagnostic challenges and therapeutic strategies for DI-ILD.
  • To discuss the evolving landscape of drug-induced lung injury.

Main Methods:

  • Literature review of drug-induced interstitial lung disease.
  • Analysis of clinical presentations, diagnostic criteria, and treatment outcomes.
  • Examination of specific drug classes associated with lung toxicity.

Main Results:

  • Diagnosis relies on drug exposure history and exclusion of other ILD causes, lacking specific markers.
  • Treatment focuses on prompt drug discontinuation and systemic glucocorticoids for severe cases.
  • Preventive strategies and risk-benefit assessments are crucial for high-toxicity drugs like checkpoint inhibitors.

Conclusions:

  • DI-ILD diagnosis requires high clinical suspicion and careful evaluation.
  • Management hinges on identifying and removing the offending agent, with steroids as a primary treatment.
  • Ongoing research is vital to understand and mitigate the risks of drug-induced lung injury.